Recipes and Stuff

Recipes, Food, Health, Lifestyle, and News

Menu
  • Industry News
  • Cakes
  • Soups
  • Vegan lifestyle
  • Indian recipes
  • Desserts
  • Blog
  • About
Menu

BerGenBio appoints Cristina Oliva as Chief Medical Officer

Posted on April 11, 2022April 11, 2022 by Kiran

BERGEN: BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announced the appointment of Cristina Oliva, MD as Chief Medical Officer (CMO), effective 25 April 2022.

Cristina joins the senior leadership team heading up clinical development of BerGenBio’s selective AXL inhibitor programs.

Cristina is a Board-certified oncologist and brings over 20 years of senior clinical development experience across large pharmaceutical, biotechnology and Clinical Research Organizations (CROs). Most recently Cristina was Vice President, Oncology and Head of Oncology Centre of Excellence at IQVIA Ltd, where she led the development of decentralized trials and established and led the IQVIA Oncology Global Scientific Advisory Board. Prior to her role at IQVIA, Cristina held senior positions leading oncology development programs for Nordic Nanovector, Takeda Pharmaceuticals, GlaxoSmithKline and Eli Lilly.

Martin Olin, Chief Executive Officer of BerGenBio, commented: “I’m delighted to welcome Cristina as our new Chief Medical Officer. Cristina’s leadership experience within oncology drug development across big pharma, biotech and CRO environments will be instrumental in executing BerGenBio’s development strategy for our AXL inhibitor programs, including our most advanced program bemcentinib, currently in phase II trials.”

On her appointment as Chief Medical Officer at BerGenBio, Cristina Oliva, MD, commented:”BerGenBio is on the frontier of developing novel, highly selective AXL inhibitors for the treatment of severe diseases such as oncology and respiratory infections. I’m very excited to join BerGenBio at this critical phase and look forward to working with the senior leadership team to help further advance its AXL inhibitor programs.”

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company’s proprietary lead candidate, bemcentinib, is a potentially first-in -class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in cancer and COVID -19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO).

www.bergenbio.com

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Xmeets Evaluation 2021
  • Cercando really love: why is sei accattivante?
  • Consejos Mantener Una unión Interesante
  • Strawberry Fudge
  • Experts stress the need for climate smart agriculture to ensure food security in Pakistan
  • Blog
  • Cakes
  • Desserts
  • Indian recipes
  • Industry News
  • Recipes
  • Soups
  • Trending Beverages
  • Uncategorized
  • Vegan lifestyle

Archives

  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
©2023 Recipes and Stuff | Theme by SuperbThemes